Join
Live feed
·
PRReleasevia Quantisnow
Eiger BioPharmaceuticals Inc. logo

Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 D-LIVR Study Results of Lonafarnib-based Treatments in Hepatitis Delta Virus (HDV) on Thursday, December 8, 2022

ByQuantisnow·Wall Street's wire, on your screen.
EIGR· Eiger BioPharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EIGR (Eiger BioPharmaceuticals Inc.) and more on Quantisnow.